VCAM-1-targeting gold nanoshell probe for photoacoustic imaging of atherosclerotic plaque in mice
Article first published online: 29 OCT 2012
Copyright © 2012 John Wiley & Sons, Ltd.
Contrast Media & Molecular Imaging
Volume 8, Issue 1, pages 27–39, January/February 2013
How to Cite
Rouleau, L., Berti, R., Ng, V. W. K., Matteau-Pelletier, C., Lam, T., Saboural, P., Kakkar, A. K., Lesage, F., Rhéaume, E. and Tardif, J.-C. (2013), VCAM-1-targeting gold nanoshell probe for photoacoustic imaging of atherosclerotic plaque in mice. Contrast Media Mol Imaging, 8: 27–39. doi: 10.1002/cmmi.1491
- Issue published online: 29 OCT 2012
- Article first published online: 29 OCT 2012
- Manuscript Accepted: 3 JUL 2012
- Manuscript Revised: 1 JUN 2012
- Manuscript Received: 23 NOV 2011
- molecular imaging;
The development of molecular probes and novel imaging modalities, allowing better resolution and specificity, is associated with an increased potential for molecular imaging of atherosclerotic plaques especially in basic and pre-clinical research applications. In that context, a photoacoustic molecular probe based on gold nanoshells targeting VCAM-1 in mice (immunonanoshells) was designed. The molecular probe was validated in vitro and in vivo, showing no noticeable acute toxic effects. We performed the conjugation of gold nanoshells displaying near-infrared absorption properties with VCAM-1 antibody molecules and PEG to increase their biocompatibility. The resulting immunonanoshells obtained under different conditions of conjugation were then assessed for specificity and sensitivity. Photoacoustic tomography was performed to determine the ability to distinguish gold nanoshells from blood both in phantoms and in vivo. Ex vivo optical projection tomography of hearts and aortas from atherosclerotic and control mice confirmed the selective accumulation of the immunonanoshells in atherosclerotic-prone regions in mice, thus validating the utility of the probe in vivo in small animals for pre-clinical research. These immunonanoshells represent an adequate mean to target atherosclerotic plaques in small animals, leading to new tools to follow the effect of therapies on the progression or regression of the disease. Copyright © 2012 John Wiley & Sons, Ltd.